#Antibody Testing trends

[markettrend24]

Antibody Testing Market Growth, Overview with Detailed Analysis 2022-2030

Antibody Testing Market Growth, Overview with Detailed Analysis 2022-2030

The Antibody Testing Market research report 2022-2030 provides an in-depth analysis of the changing trends, opportunities, and challenges influencing the growth over the next decade. The study includes a detailed summary of each market along with data related to demand, supply and distribution. The report examines Antibody Testing market growth strategies adopted by leading manufacturers which…

[lalsingh228-blog]

Antibody Testing Market Projected to Show Strong Growth

A Latest intelligence report published by AMA Research with title "Global Antibody Testing Market Outlook to 2028. A detailed study accumulated to offer Latest insights about acute features of the Antibody Testing market. This report provides a detailed overview of key factors in the Global Antibody Testing Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development.

Definition: Antibodies are immunoglobulins, which are Y-shaped proteins formed by the immune system to help protect the body from foreign invaders. An antibody test is a blood test that tests for the existence of antibodies. When the body battles an infection, such as COVID-19, or when patients undergo a vaccine, such as a flu shot, antibodies are formed. Which is how a virus's immunity is created. These tests are also known as serology tests. After the illness has passed, these checks are deployed to assess the incidence of disease in a population. Serology examinations include blood samples, which are obtained from a person's arm or a finger stick. Prevalence of Covid and SARS cases are major factors owing to growth in Antibody Testing market. Major Players in This Report Include, Alere Inc. (United States), Hoffmann La Roche , Abbott Laboratories, Bio-Rad Laboratories Inc. (United States), ERBA Diagnostics Inc. (United States), Trinity Biotech plc (Ireland), Thermo Fisher Scientific Inc. (United States), Antibodies Inc. (United States), EUROIMMUN AG (Germany), Immuno Concepts (United States). Free Sample Report + All Related Graphs & Charts @ : https://www.advancemarketanalytics.com/sample-report/167779-global-antibody-testing-market Global Antibody Testing the manufacturing cost structure analysis of the market is based on the core chain structure, engineering process, raw materials and suppliers. The manufacturing plant has been developed for market needs and new technology development. In addition, Global Antibody Testing Market attractiveness according to country, end-user, and other measures is also provided, permitting the reader to gauge the most useful or commercial areas for investments. The study also provides special chapter designed (qualitative) to highlights issues faced by industry players in their production cycle and supply chain. The Global Antibody Testing Market segments and Market Data Break Down are illuminated below: by Type (Assay Kits & Reagents, Software & Services), Disease (Covid-19, Human Immunodeficiency Virus (HIV), Crest Syndrome, Other), End Use (Hospitals, Clinical Laboratories, Test Centers), Technique (Inova Diagnostics (United States), Zeus Scientific Inc. (United States), Ortho Clinical Diagnostics (Unites States)) Market Drivers Prevalence of SARS-CoV-2 Cases

Emergence of Advance and Effective Techniques Market Trend Technical Progress in Medical Industry

Heavy Investments in Research & Development Opportunities Low Penetration in Remote Regions Challenges Sudden Demand Shocks Such as Due to Covid-19 Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/167779-global-antibody-testing-market

Geographically World Global Antibody Testing markets can be classified as North America, Europe, Asia Pacific (APAC), Middle East and Africa and Latin America. North America has gained a leading position in the global market and is expected to remain in place for years to come. The growing demand for Global Antibody Testing markets will drive growth in the North American market over the next few years.

In the last section of the report, the companies responsible for increasing the sales in the Global Antibody Testing Market have been presented. These companies have been analyzed in terms of their manufacturing base, basic information, and competitors. In addition, the application and product type introduced by each of these companies also form a key part of this section of the report. The recent enhancements that took place in the global market and their influence on the future growth of the market have also been presented through this study. Report Highlights:

Comprehensive overview of parent market & substitute market

In-depth market segmentation (Trends, Growth with Historical & Forecast Analysis)

Recent industry trends and development activity

Competitive landscape (Heat Map Analysis for Emerging Players & Market Share Analysis for Major Players along with detailed Profiles)  

Strategic Points Covered in Table of Content of Global Antibody Testing Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Antibody Testing market

Chapter 2: Exclusive Summary – the basic information of the Antibody Testing Market.

Chapter 3: Changing Impact on Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Antibody Testing;

Chapter 4: Presenting the Antibody Testing Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2017-2022

Chapter 6: Evaluating the leading manufacturers of the Antibody Testing market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2023-2028)

……���……. Buy this research @ https://www.advancemarketanalytics.com/buy-now?format=1&report=167779 Key questions answered

Who are the Leading key players and what are their Key Business plans in the Global Antibody Testing market?

What are the key concerns of the five forces analysis of the Global Antibody Testing market?

What are different prospects and threats faced by the dealers in the Global Antibody Testing market?

What possible measures players are taking to overcome and stabilize the situation?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[covid-safer-hotties]

Experts urge people to mask up as Southern California sees COVID-19 surge - Published Aug 6, 2024

Health experts are urging community members to exercise greater caution and mask up as Pasadena and the rest of Los Angeles County deal with a sharp increase in COVID-19 cases driven in large part by a highly contagious new variant.

This variant, KP.3.1.1, is causing a surge, especially among those who have previously avoided the virus. Experts attribute the rise to the variant’s increased transmissibility and its abilities to evade some immune defenses, combined with a general decline in immunity within the population.

“In the last few weeks, we, meaning L.A. County, including Pasadena, have seen an increase in the total number of SARS COV-2 cases being reported in our laboratories, but also in our wastewater detection,” Dr. Matt Feaster, division manager of Epidemiology and Disease Control in the Pasadena Public Health Department, said Monday, Aug. 5.

This reflects the general trend in the area. Last week, the level of coronavirus particles in wastewater, a proxy of COVID-19 cases in a community, rose to 44% of last winter’s peak, more than double the 17% reported in the first week of July, the LA County Public Health Department said in an emailed statement Monday.

Currently, L.A. County’s wastewater coronavirus concentration is around 82% of last summer’s peak, which took place in early September. Over the past four weeks, the daily average of COVID-19 cases, deaths and hospitalizations have doubled. Last week, LA County reported an average of 452 daily COVID-19 cases, up from 229 cases four weeks ago, county officials said.

Pasadena has seen an average of around five reported cases per day, Feaster said. However, this is likely a “big underestimate” of the actual number of infections in the community, because it only includes those who have taken a PCR test, and exclude those using at-home tests or who haven’t tested, both of which go unreported, he said.

The recent rise in COVID-19 cases are caused in part by the new variant KP.3.1.1, an off-shoot of Omicron, Dr. Elizabeth Hudson, regional chief of infectious diseases at Kaiser Permanente Southern California, headquartered in Pasadena, wrote in an emailed response Monday.

KP.3.1.1 has recently become the dominant variant across the country, according to data from the Centers for Disease Control and Prevention. KP.3.1.1 is a sublineage of KP.3, which was the previous dominant variant. Together, KP.3.1.1 and KP.3 made up 27.8% and 20.1% of Omicron cases across the country for the period of July 21 to Aug.3, CDC data shows.

“This variant is more infectious and it’s coming at a time when overall immunity, both natural and vaccine-induced, is at a nadir,” Hudson said. “This, combined with people engaging in the usual summertime activities without any mitigation techniques (very few are wearing masks), means that this variant is able to spread quickly. We are also seeing more of the so-called ‘Novids’ or those who’ve never had COVID getting it now.”

The surge is affecting people across all ages, although most do not require hospitalization, Hudson said. Those who are hospitalized tend to be older and more likely to have compromised immune systems, she added.

Both KP.3.1.1 and KP.3. belong to a new class of variant called the “FLiRT” variants, which are notable for their combination of mutations that help the virus evade antibodies while potentially improving its ability to bind to and enter cells, researchers at John Hopkins said.

“It’s in the virus’s interest to become more infectious and to dodge some of the vaccine immunity that we have out there,” Dr. Kimberly Shriner, medical director of infection prevention at Huntington Health, said in a phone interview last week. “So, as much as everybody wants the COVID pandemic to be over, it really isn’t over.”

Read the rest at either link! (Covidsafehotties is always free from distractions like in-line adds!)

[fictionplumis]

The good news!

I got my muscle biopsy results back today, which is pretty lucky because I was supposed to see my rheumatologist today to go over them. The results?

"The muscle biopsy is nearly normal aside from focal endomysial inflammatory infiltrates by T-lyphocytes and rare macrophages are seen. Although these changes are subtle, they may indicate an inflammatory myopathy in the appropriate clinical context."

Paired with my blood test that popped positive for an antibody related to dermatomyositis, which is an inflammatory myopathy that often includes T-lyphocytes in skeletal muscle tissue, makes this a pretty clear diagnosis in regards to an autoimmune thing.

The bad news...

A week before my appointment with my rheumatologist, his office called to tell me that my appointment was cancelled because the office owner had decided to shut down all the office locations effective immediately. This had nothing to do with my rheumatologist, it was a business decision on the part of the practice owner.

My mom did some digging and found out the office has done this before! They get into some kind of financial or legal trouble, shut down all their office locations, go through the process of registering under a new name, and open back up again. They do this every few years. My rheumatologist was hired in February of this year after moving to my location, so he's only worked there and lived in the area for a couple of months, and most likely had no idea that this was a trend with the practice.

The thing is, dermatomyositis is one of his specialties within rheumatology. He's published research and shit about it. Which is the main reason why I went with him and why I would prefer him handling my treatment over anyone else in the area.

My mom found him on facebook and sent him a friend request and a PM, but it seems like he's only on there once every couple of months, so...

I'll be looking elsewhere for a rheumatologist in the meantime. At least now we have all the tests and proof of what I have.

[meret118]

 At Caesars Sidnai, Pimentel and his colleagues created a diagnostic blood test to diagnose IBS. While he said it’s not a definitive diagnosis, it can provide one with more than 90% certainty.

This is in part because of a rise in research showing a clear link between food poisoning and IBS — a less talked about cause of IBS and “gut health” on #guttok. Pimentel said it’s estimated that food poisoning triggers at least 60 percent of all IBS on the “diarrhea-mixed side.” In this kind of situation, a person may have gone on a trip and got food poisoning. If their bowel movements never return to normal, that’s IBS. Researchers have identified a toxin that’s responsible for that type of IBS, and antibodies that are created from the toxin. 

. . .

For the other people who don’t get IBS from food poisoning, Pimentel said it could be that food sensitivities are the driver behind it. Mast cells, which are special cells that are part of the allergic system of the gut, tend to be higher in some IBS patients.

“And then some patients just have naturally sensitive guts,” he said. “That's called visceral hyperalgesia.” 

[flyonthewallmedstudent]

Helicobacter Pylori

Spicing things up a bit with a Gram Negative Helical/spiral Bacteria

Epidemio:

up to 50% of the population worldwide, but even more in endemic countries/the 3rd world

it can cloud differentials, as it can be asymptomatic unless it caues peptic ulcer disease, in which case the infection may have been decades prior to detection - so you have to interpret serology with a grain of salt (it may not be the culprit of acute infection)

often picked up in early childhood and lingers without treatment for dcades

by contrast, 5% of children in the US have had it, so it may change your clinical decision making depending on where your patient grew up

In australian populations, up to 30% have it, but again, high frequency in older migrants, lower socioeconomic status etc.

Transmission:

faecal oral or even sexual (did not know that one)

increased risk:

lower socioeconomic status/growing up in a developed country

family history of infection and gastric cancer

What it does:

cause ulceration (peptic ulcer disease)

and inflammation or gastritis

due to it's helical shape and flagella, it can penetrate the mucosal lining

Trivia/History:

discovered by Australians in Western Australia in the 1980s

To quote the IM physician, Barry Marshall, in the face of skepticism that a bacteria could survive the stomach's acidic environment: "everyone was against me, but I knew I was right"

After failing to publish and some lab snaffus, he decided to do a Jonas Salk and swallow a broth of Hpylori himself. Of course this last experiment was published in an Australian journal.

At any rate, it is now widely accepted that Hpylori is linked to PUD and gastric cancer and by 2005, the two Australians who found the bacteria received the Nobel prize in medicine

we now know so much more about the pathogen with advancements in microbiology

they also came up with the urease breath test for it

Clinical presentation:

asymptoamtic

symptom onset occurs after gastritis and peptic ulcer disease develop: nausea, vomiting, dyspepsia, abdo pain, or at the extreme when the lining has eroded, bleeding/haematemesis

IMage source

Important differentials

coeliac's

Crohn's

nSAID induced gastritis

reflux

lactose intolerance

eosinophilic oesophagitis (sooo rare, usually a/w dysphagia)

Investigations (all with relatively good/high sens and spec)

H pylori antigens in stool

serology (antibodies in serum, urine) --> usually IgG, hence can remain positive for years even post eradication

urease breath test

if a scope was involved due to PUD, then histopathology and culture (reduced sensitivity if treated with PPI in 2/52 prior or Abx 4/52 prior)

actually had no idea they breathed into little bags.

Treatment:

triple therapy - PPI, amoxicillin and clarithromycin for 14 days, in penicillin allergy replace amox with metro (increasing resistance is why metro is not first line in some countries - refer to local guidelines made based on local Abx resistance trends)

In patients younger than 50, it can be cost effective to treat if they have reflux on testing (if there's a high pretest probability - see increased risk groups) given the life time risk of PUD & gastric cancer, can also reduce risk of GIB

balance of risk/benefit: will it significantly improve QOL or will risks of ADRs outweigh the benefits (eg frail, elderly, multiple comorbidities)

when used in those with PUD - improves ulcer healing, recovery and prevents relapse

in simple ulcers, triple therapy is all that is required in more chronic complex ones --> 8/52 of PPI is also recommended to prevent recurring of bleeding etc.

not treating can lead to relapse and complications like bleeding/perforation/cancer risk

Complications

rarely, it can cause gastric adenocarcinoma as a known carcinogen

aka MALT lymphoma - mucosa-associated lymphoid tissue

this resolves with triple therapy (Usually)

consider it in family histories of gastric cancer

life time risk of gastric cancer at 2% and 15-20% risk of peptic ulcer disease

Wish the acronym wasn't MALT. But could be a good way to remember it. MALT, tasty, gastritis and Hpylori.

Follow-up

test for eradication 2 weeks post with stool antigen or urease breath test (serology less effective as the IgGs can remain positive for years) but that's on holding the PPI for 1/52 to prevent a false negative, some countries want both tests

in resistance or relapse there's salvage therapy, usually with bismuth or a quinolone.

Sources:

Wikipaedia - I havent covered pathophysio or it's cellular mechanisms and virulence factors, but there's a good overview in wiki

StatPearls (more paeds focused in this one)

CDC guidelines

Australian Therapeutic guidelines (Paywalll rest above are free)

[wisdomfish]

Unnatural: ‘The Ugly Truth About Gay Male Sex’

According to the CDC:

“Anal sex is the riskiest type of sex for getting or transmitting HIV.”

Causes “immunosuppression…” …the immunosuppression in homosexual males that is reported even in apparently healthy or HTLV-III-antibody-negative groups may arise from seminal PGE2 received during anal intercourse. “Prostaglandin E2 administered via anus causes immunosuppression in male but not female rats: a possible pathogenesis of acquired immune deficiency syndrome in homosexual males.” S Kuno, et al. Proc Natl Acad Sci U S A. 1986 Apr; 83(8): 2682–2683.

Gay sex is always getting kinkier and more violent:

There is a rising trend in high risk sexual behavior among men who have sex with men (MSM), with concomitant use of recreational drugs. Activities include fisting and unprotected anal intercourse with a partner who is HIV serodiscordant or of unknown status. “Sexual trauma associated with fisting and recreational drugs.” Cohen CE, Giles A, Nelson M. Sex Transm Infect. 2004 Dec;80(6):469-70.

Gay marriage is no safeguard against HIV:

Over 50% of HIV transmissions in US gay men are from main sexual partners. “Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities.” Sullivan PS et al. AIDS 23 (online edition), 2009.

Besides HIV, gay sex causes homosexual men to be at an increased susceptibility for a variety of sexually transmitted diseases:

Compared with other sexually active adults, men who have sex with men (MSM) are more frequently infected with several pathogens including cytomegalovirus, hepatitis B virus, and Kaposi sarcoma-associated herpesvirus…MSM in a San Francisco population-based cohort were interviewed regarding use of saliva by the insertive partner as a lubricant in various anal sexual practices. Among 283 MSM, 87% used saliva as a lubricant in insertive or receptive penile-anal intercourse or fingering/fisting at some point during their lifetime; 31%-47% did so, depending upon the act, in the prior 6 months. “Use of Saliva as a Lubricant in Anal Sexual Practices Among Homosexual Men” Lisa M Butler, et al. JAIDS Journal of Acquired Immune Deficiency Syndromes 50(2):162-7 • February 2009

The majority of gay men engage in anal sex; and there is no right way to do it:

In the United States alone, receptive anal intercourse is practiced in up to 90 percent of gay and other men who have sex with men, according to International Rectal Microbicides Advocates…In one study involving nearly 900 men and women in Baltimore and Los Angeles, the researchers found that those who used lubricants were three times more likely to have rectal sexually transmitted infections (STIs). Another study that subjected popular over-the-counter and mail-order lubricants to rigorous laboratory tests discovered that many of the products were toxic to cells and rectal tissue. “Use of lubricants with anal sex could increase risk of HIV.” Microbicides 2010 (International Conference on Microbicides) May 25, 2010

If you are a heterosexual male, your likelihood of contracting HIV is relatively small:

Over the 6 years there were 33,681 HIV tests performed on men, of which 17,958 tests were for heterosexual men. From these heterosexual men, nine tested positive for the first time…These nine cases included six men who had had sex with a female partner from the following countries: Thailand, Cambodia, China, East Timor, Botswana and South Africa. Two men had injected drugs and one had a HIV-positive female partner. “HIV is rare among low-risk heterosexual men and significant potential savings could occur through phone results.” Bush MR et al. Sex Health. 2010 Dec;7(4):495-7

Young gay men are more likely to contract HIV from their older male partners:

…the Centers for Disease Control and Prevention has shown a resurgence of the HIV epidemic particularly in young MSM…MSM participants with recent HIV infection reported having sex with older partners. “A Major HIV Risk Factor for Young Men Who Have Sex With Men Is Sex With Older Partners” Brian J. Coburn, PhD and Sally Blower, PhD J Acquir Immune Defic Syndr. 2010;54:113–114

A majority of gay men do not regularly practice “safe-sex:”

Among men whose most recent sexual encounter was with a main partner, 83% reported having anal sex, and 49% reported having anal sex without a condom during that encounter. Among men whose most recent sexual encounter was with a casual partner, 68% reported having anal sex, and 24% reported having anal sex without a condom during that encounter. “HIV Risk, Prevention, and Testing Behaviors National HIV Behavioral Surveillance System Men Who Have Sex with Men” 20 U.S. Cities, 2011

Young gay men are more likely than heterosexuals to engage in sex with an older partner:

Over one-half (52.0%) of MSM aged 18–24 reported a recent male anal sex partner who was >5 years older…By contrast, only 7.9% of heterosexual men and 10.0% of heterosexual women in this age group reported a recent partner who was >5 years older. “A comparison of sexual behavior patterns among men who have sex with men and heterosexual men and women” Sara Nelson Glick, et al. J Acquir Immune Defic Syndr. 2012 May 1; 60(1): 83–90.

Sexually transmitted diseases among gay men are becoming antibiotic resistant:

Among 79 cases of Shigella sonnei, 56 occurred in HIV-infected MSM, while 23 were observed in HIV-negative MSM. High resistance rates (>90 %) were found for doxycycline, tetracycline, aminoglycosides, all cephalosporins of first and second generations tested, and trimethoprim/sulfamethoxazole. In total, 54 % of cases were resistant to ciprofloxacin. Compared to negative subjects, HIV-infected MSM had a significantly higher rate of quinolone resistance. “High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM” C. Hoffmann, et al. Infection. October 2013, Volume 41, Issue 5, pp 999–1003

More gay men are having unprotected anal intercourse:

Unprotected anal sex at least once in the past 12 months increased from 48% in 2005 to 57% in 2011. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report (MMWR) HIV Testing and Risk Behaviors Among Gay, Bisexual, and Other Men Who Have Sex with Men — United States November 29, 2013 / 62(47);958-962

A majority of gay men report more than two recent sex partners:

In the last ninety days, 32.7% men reported no sexual partners, 25.8% reported one-to-two sexual partners, and 41.5% reported more than two sexual partners. Most men reported meeting their sexual partners both online and offline. Most MSM (69.4%) reported less than two unprotected anal sex male partners in the last 90 days, while 73.1% reported protected anal sex with one or more men. The products most commonly used for douching – water, soap, and saline — are those, which laboratory and clinical studies have identified as damaging the epithelium. Thus, douching appears a candidate behavior that may plausibly influence both HIV and other STI transmission among MSM. “Enema Use among Men who have Sex with Men: A behavioral epidemiologic study with implications for HIV/STI prevention” Syed W Noor and Simon Rosser Arch Sex Behav. 2014 May; 43(4): 755–769.

Gonorrhea and chlamydia are becoming antibiotic resistant in gay men:

Extragenital GC/CT was common among MSM attending STD clinics…Of MSM tested, 11.1% tested positive for urogenital GC, 7.9% for pharyngeal GC, 10.2% for rectal GC, 8.4% for urogenital CT, 2.9% for pharyngeal CT, and 14.1% for rectal CT. “Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men–STD Surveillance Network, United States, 2010-2012.” Patton ME, et al. Clin Infect Dis. 2014 Jun;58(11):1564-70.

Younger gay men are likely to have an older first-time lover:

The median age was 19 years. The median age at first insertive or receptive anal intercourse was 17 years. Half of men reported sex with mainly older men: these men were more likely to engage in receptive anal intercourse (48% vs. 25%) than other men. Most men had engaged in insertive (87%) and receptive (85%) anal intercourse in the prior 12 months with 60% and 53% reporting inconsistent condom use with insertive and receptive anal intercourse partners, respectively. “Sexual behaviors and risk for sexually transmitted infections among teenage men who have sex with men.” Zou H, et al. J Adolesc Health. 2014 Aug;55(2):247-53.

Condom use does not guarantee safety:

Among Ontario MSM in 2009, an estimated 92,963 HIV-negative men had 1,184,343 episodes of anal sex with a condom and 117,133 anal sex acts without a condom with an HIV-positive partner. Of the 693 new HIV infections, 51% were through anal sex with a condom, 33% anal sex without a condom and 16% oral sex. “HIV Transmission among Men Who Have Sex with Men due to Condom Failure” Robert S. Remis, et al. Published: September 11, 2014

Oral sex isn’t a “safer” alternative:

…oral sex has an important role in sustaining gonorrhea in a population of MSM by providing a pool of untreated asymptomatic infection. “Oral and Anal Sex Are Key to Sustaining Gonorrhoea at Endemic Levels in MSM Populations: A Mathematical Model” B Hui, et al. Sex Transm Infect 91 (5), 365-369. 2015 Jan 16.

Although the risks of receptive anal sex are well known, gay men continue to engage in such behaviors:

70% of MSM reported receptive anal intercourse at least once in the past 3 months… “Consistency of Condom Use During Receptive Anal Intercourse Among Women and Men Who Have Sex With Men: Findings From the Safe in the City Behavioral Study.” DʼAnna LH, et al. Sex Transm Dis. 2015 Jul;42(7):393-9.

Difficult to treat chronic diarrhea has been reported in gay men:

Shigella flexneri is an emerging pathogen in men who have sex with men; recent outbreaks related to sexual practices have been noted in this population in the UK and other developed countries. While majority of cases of Shigellosis present with gastroenteritis, some vulnerable patients with underlying immunosuppression can get complications like bacteraemia and may present atypically as an acute surgical emergency. “Invasive shigellosis in MSM.” Serafino Wani RL, et al. Int J STD AIDS. 2015 Oct 1.

Anal sex causes incontinence:

The findings support the assessment of anal intercourse as a factor contributing to fecal incontinence in adults, especially among men.” “Anal Intercourse and Fecal Incontinence: Evidence from the 2009-2010 National Health and Nutrition Examination Survey.” Markland AD, et al. Am J Gastroenterol. 2016 Jan 12.

HPV, a sexually transmitted disease typically found in women, is epidemic in the gay male community:

Anal HPV was highly prevalent in MSM (HIV positive, 88% and HIV negative, 78%). “A prospective study of anal cancer screening in HIV positive and negative men who have sex with men; results of Analogy.” Schofield AM, et al. AIDS. 2016 Feb 1.

A majority of HIV+ gay men have experienced some form of anal trauma:

75% of the men had abnormal anal cytological/histological results. 41% presented with low-grade, 24% with high-grade anal dysplasia… “The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany.” Fuchs W, et al. J Eur Acad Dermatol Venereol. 2016 Feb 1.

35% of gay men have a sexually transmitted infection:

One third (35%) were positive for STI. STI prevalence was significantly associated with using sex slings, felching, group sex, fisting, anonymous sex, and sex toys. HIV prevalence was 17% and was significantly associated with fisting, felching, enemas, and group sex. “Beyond Anal Sex: Sexual Practices of Men Who Have Sex With Men and Associations With HIV and Other Sexually Transmitted Infections.” Rice CE, et al. J Sex Med. 2016 Feb 4.

Gay men have increased prevalence of antibiotic resistant gonorrhea:

A total of 5,093 isolates were collected in 2014. Of these, 25.3% were resistant to tetracycline, 19.2% to ciprofloxacin, and 16.2% to penicillin (plasmid-based, chromosomal, or both)… The percentage of isolates resistant to tetracycline, ciprofloxacin, penicillin, or all three antimicrobials, was greater in isolates from MSM than from MSW. “Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance – The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.” Kirkcaldy RD, et al. MMWR Surveill Summ. 2016 Jul 15;65(7):1-19.

Younger gay men are less likely to practice “safe-sex;” but are more likely to use drugs:

When compared to MSM 50 years or older (HIV prevalence 2.5%), significantly higher rates of unprotected anal intercourse, bacterial STI and stimulant substance use were reported among young MSM, whereas total number of partners during the last 12 months did not differ. While higher rates of stimulant substance use may explain the higher rates of condomless anal sex among young MSM, the observation of a recent study that condom use errors and problems, such as breakage and slippage were very common among young MSM… “HIV Infection Rates and Risk Behavior among Young Men undergoing community-based Testing in San Diego” Martin Hoenigl et al. Sci Rep. 2016; 6: 25927.

In the US, 60% of syphilis cases were in 2% of the general population – gay men:

In men, sores can occur on or around the penis, around the anus or in the rectum, or in or around the mouth. These sores can be painless, so it is possible to have them and not notice them. Correct use of condoms can reduce the risk of syphilis if the condom covers the sores. However, sometimes sores occur in areas not covered by a condom. It is still possible to get syphilis from contact with these sores Syphilis & MSM (Men Who Have Sex With Men) – CDC Fact Sheet (January 2017)

[health-views-updates]

Biological Safety Testing Products and Services Market 2024 | Upcoming Trend in Biological Safety Testing Products and Services Industry by an Expert

The global biological safety testing products and services market is on a robust growth trajectory, valued at $4.42 billion in 2023 and projected to reach $10.51 billion by 2032. This remarkable growth reflects a compound annual growth rate (CAGR) of 10.10% over the forecast period from 2024 to 2032, driven by the increasing demand for safety and efficacy testing across the biopharmaceutical and healthcare sectors.

Biological safety testing is essential for ensuring that medical products, including pharmaceuticals, vaccines, and medical devices, meet stringent safety and efficacy standards before reaching the market. The market encompasses a wide range of testing services, including sterility testing, endotoxin testing, and biocompatibility assessments, all critical for regulatory compliance.

Key Market Drivers

Increasing Biopharmaceutical R&D Activities: The rising investment in biopharmaceutical research and development is a significant factor propelling the market. As the industry focuses on innovative therapies, including monoclonal antibodies, gene therapies, and cell therapies, the need for rigorous biological safety testing becomes paramount. These testing services help ensure that new products are safe for human use, fostering trust in the healthcare system.

Regulatory Compliance and Safety Standards: Stringent regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global health authorities are driving the adoption of biological safety testing services. Compliance with these regulations is critical for companies looking to launch new medical products, creating a steady demand for testing services that ensure product safety and efficacy.

Growing Concerns About Contamination and Quality Assurance: The increasing prevalence of product recalls due to contamination and safety issues has heightened awareness about the importance of biological safety testing. Companies are now more vigilant in their quality assurance processes, recognizing that thorough testing is essential to maintain product integrity and safeguard public health.

Expansion of the Healthcare Sector: The ongoing expansion of the healthcare sector, particularly in emerging markets, is creating new opportunities for biological safety testing services. With the growth of healthcare facilities and the increasing production of biologics and biosimilars, the demand for reliable testing solutions is expected to rise significantly.

Access Free Sample Report: https://www.snsinsider.com/sample-request/4483 

Challenges and Opportunities

While the market shows strong potential, it faces challenges such as the high cost of testing services and the need for specialized expertise. However, advancements in technology, including automation and digitalization, are likely to streamline testing processes, reduce costs, and enhance the accuracy of results.

Moreover, the increasing adoption of 3D cell culture systems and organ-on-a-chip technologies offers opportunities for innovative testing solutions. These advancements are expected to improve the efficiency and effectiveness of biological safety testing, providing companies with the tools they need to ensure product safety.

Regional Insights

North America holds the largest share of the biological safety testing market, driven by the presence of leading biopharmaceutical companies, advanced research facilities, and stringent regulatory standards. Europe follows closely, with significant investments in healthcare and biotechnology sectors. The Asia-Pacific region is expected to experience the highest growth rate during the forecast period, supported by the expansion of healthcare infrastructure and increasing research activities in countries such as China, India, and Japan.

Future Outlook

As the demand for innovative biopharmaceutical products continues to rise, the biological safety testing products and services market is set for significant growth. With a projected CAGR of 10.10% from 2024 to 2032, the market is poised to see substantial advancements in testing technologies, helping to meet the increasing demand for safety and efficacy in healthcare products.

In conclusion, the biological safety testing products and services market is entering a dynamic phase of growth, with a valuation expected to rise from $4.42 billion in 2023 to $10.51 billion by 2032. This growth is driven by regulatory compliance, the expansion of biopharmaceutical R&D, and the need for rigorous quality assurance in an increasingly complex healthcare landscape

Other Trending Reports

Dental Suction Systems Market Size

Cosmeceuticals Market Size

Cell Therapy Market Size

Growth Hormone Deficiency Market Size

[credenceresearchdotblog]

The Immortalized Cell Line Market is projected to grow from USD 4485 million in 2024 to an estimated USD 6867.426 million by 2032, with a compound annual growth rate (CAGR) of 5.47% from 2024 to 2032.The immortalized cell line market has been experiencing substantial growth over the past few years, driven by rising demand for biologics, advanced drug discovery processes, and an increasing prevalence of chronic diseases. Immortalized cell lines are cultured cells that can divide indefinitely and are widely used in research and biotechnology applications. They have become indispensable tools for cancer research, vaccine production, toxicology testing, and gene therapy development. This article delves into the key trends, drivers, challenges, and future prospects of the immortalized cell line market.

Browse the full report at https://www.credenceresearch.com/report/immortalized-cell-line-market

Key Drivers of Market Growth

1. Rise in Chronic Diseases The growing global burden of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, has fueled the demand for immortalized cell lines. These cell lines are crucial for understanding disease mechanisms, testing potential treatments, and developing personalized medicine. The cancer segment, in particular, is a significant contributor to the market, as immortalized cancer cell lines are essential for studying tumor biology and drug resistance.

2. Advancements in Biotechnology and Drug Discovery Immortalized cell lines play a pivotal role in modern drug discovery and development. With the emergence of high-throughput screening technologies, pharmaceutical companies can now test a large number of potential drug compounds quickly and efficiently. This has been especially relevant in the development of targeted therapies and immunotherapies, which rely on cellular models to identify and validate drug targets.

3. Increasing Demand for Biologics Biologics, such as monoclonal antibodies, vaccines, and recombinant proteins, have emerged as a significant class of therapeutics. The production of biologics requires the use of immortalized cell lines as bioreactors for the production of large quantities of proteins. The expanding biologics pipeline, driven by increasing regulatory approvals, is further boosting the demand for high-quality and stable immortalized cell lines.

4. Advances in Gene Editing Technologies The advent of CRISPR-Cas9 and other gene-editing tools has revolutionized the field of cellular biology, allowing scientists to create custom immortalized cell lines with specific genetic modifications. This has opened new avenues for research, enabling the creation of disease models that closely mimic human conditions. Such cell lines are invaluable for studying gene function, conducting functional genomics studies, and developing precision medicine approaches.

Key Challenges

Despite the promising growth, several challenges persist in the immortalized cell line market:

1. Ethical Concerns: The use of certain cell lines, such as those derived from human embryos or aborted fetal tissue, raises ethical issues. These concerns can limit research or create regulatory hurdles. 2. Contamination and Misidentification: Immortalized cell lines can be prone to contamination, and misidentification of cell lines is a well-documented issue in the scientific community. This can lead to unreliable data and wasted resources, highlighting the need for improved cell line authentication processes.

3. Regulatory Hurdles: The use of genetically modified cell lines and the production of biologics in cell-based systems are subject to stringent regulatory scrutiny. Meeting the necessary regulatory requirements can slow down product development and increase costs.

Future Outlook

The future of the immortalized cell line market looks promising, with advancements in biopharmaceuticals, personalized medicine, and regenerative therapies poised to drive growth. The integration of artificial intelligence (AI) and machine learning into drug discovery processes will also create new opportunities for utilizing immortalized cell lines in innovative ways. Furthermore, as the demand for biologics continues to rise, the need for robust, scalable, and high-yield cell line systems will grow.

Key Player Analysis:

ATCC (American Type Culture Collection Inc.) (US)

Corning Incorporated

Creative Bioarray

European Collection of Authenticated Cell Cultures (ECACC) (Europe)

General Electric Company

InSCREENeX GmbH

Lonza Group, AG (Switzerland)

Merck KGaA (Germany)

Public Health England

Sartorius AG (Germany)

Selexis SA (Switzerland)

Sigma-Aldrich Co.

TCC

Thermo Fisher Scientific (US)

Valneva (France),

WuXi App Tec(China)

Segmentation:

By Method,

Viral,

Non-viral,

Hybrid methods.

By Application,

Drug discovery and development,

Cancer research,

Tissue engineering.

By End User,

Pharmaceutical and biotechnology companies,

Academic and research institutions,

Contract research organizations (CROs).

By Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/immortalized-cell-line-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[colinwilson11]

Antibody Discovery: Biotech  Poised For Significant Growth New  Insights Reveal Promising Trends

Developing new antibody therapies requires an intricate multi-step process. The journey begins with identifying a promising disease target, typically a protein involved in disease pathogenesis. Researchers then screen large libraries of synthetic or natural antibodies to find those that bind strongly and selectively to the target. Lead candidates are selected and undergo rounds of modification and testing to optimize their binding affinity and other desirable properties.

During this stage, various techniques are employed to enhance the Antibody Discovery in vitro such as affinity maturation, epitope binning, and humanization. Promising modified candidates progress to extensive preclinical testing in disease-relevant models to evaluate safety and efficacy. Top candidates demonstrating therapeutic potential are selected as development candidates to undergo formal Investigational New Drug (IND)-enabling studies in preparation for clinical trials.

Generating High Quality Lead Antibodies 

One of the most critical early steps is obtaining high quality lead antibodies with the biophysical properties required for drug development. While hybridoma technology has traditionally been the method of choice, newer platform technologies like phage display and yeast surface display have gained prominence in recent years. 

These techniques allow for screening immense libraries exceeding what is possible with hybridomas. This enables the discovery of antibodies with greater binding affinity, selectivity for the target epitope, developability parameters, and other optimized properties essential for drug candidates. The platforms also offer advantages like the ability to rapidly humanize mouse antibodies and interrogate structure-function aspects.

Partnering For Pipeline Growth And Commercialization 

Most biotech companies focus on the early discovery and preclinical phases of antibody development due to significant capital requirements of later stages. Therefore, partnerships remain a mainstay business strategy to fund advancement into the clinic and expand commercialization opportunities.

Upfront payments, cost-sharing agreements, and escalating milestone payments are common financial structures for R&D partnerships. Biotechs also license antibodies to larger pharma players for regional or global commercialization. This allows the original developers to leverage the resources of larger partners while retaining upside through royalties on product sales.

Looking Ahead 

With major unmet needs across disease areas and recent therapeutic successes, antibody drugs continue gaining prominence. Continued technology advances in high-throughput screening platforms, structural analysis and in silico modeling are helping generate better optimized antibody hits earlier. As the field matures, more predictive preclinical efficacy models and biomarkers may further accelerate clinical translation. 

If large studies continue validating monoclonal antibodies, the  outlook remains hugely promising. With their capacity for exquisitely targeting disease pathways, antibodies have arguably the greatest therapeutic potential of any biologic class. As such, antibody discovery will assuredly remain an area of intensive research and business activity in the biopharma  for years to come.

Get more insights on this topic:  https://www.trendingwebwire.com/antibody-discovery-navigating-the-journey-from-antigen-discovery-to-effective-treatment-a-look-into-current-research-and-developments/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[omshinde5145]

Chromatography Resin Market Size, Trends, Revenue Share Analysis, Forecast, 2024–2030

The Chromatography Resin Market was valued at USD 2.6 billion in 2023-e and will surpass USD 4.4 billion by 2030; growing at a CAGR of 7.7% during 2024 - 2030. The report focuses on estimating the current market potential in terms of the total addressable market for all the segments, sub-segments, and regions. In the process, all the high-growth and upcoming technologies were identified and analyzed to measure their impact on the current and future market. The report also identifies the key stakeholders, their business gaps, and their purchasing behavior. This information is essential for developing effective marketing strategies and creating products or services that meet the needs of the target market.

Chromatography is a laboratory technique for the separation of a mixture into its components. Chromatography resin is a medium used in the column chromatography method, which includes ion exchange, affinity, and size exclusion chromatography. These resins are essential for purifying proteins, nucleic acids, and other biomolecules, making them indispensable in various industries.

Read More about Sample Report: https://intentmarketresearch.com/request-sample/chromatography-resin-market-3154.html

Key Drivers of Growth

Biopharmaceutical Boom: The rise in biopharmaceutical production, including monoclonal antibodies, vaccines, and recombinant proteins, has significantly boosted the demand for chromatography resins. These resins play a crucial role in the purification processes, ensuring the safety and efficacy of biopharmaceutical products.

Technological Advancements: Innovations in chromatography techniques and resin development have enhanced the efficiency and effectiveness of purification processes. Advances such as multi-modal resins, which combine different modes of interaction, have expanded the applications of chromatography.

Regulatory Compliance: Stringent regulatory requirements for drug approval and quality control in the pharmaceutical and food industries necessitate the use of reliable and efficient purification methods. Chromatography resins, known for their precision and reliability, are in high demand to meet these standards.

Environmental and Food Safety: The growing emphasis on environmental monitoring and food safety has increased the use of chromatography resins in testing and analysis. These resins help detect contaminants and ensure the quality of water, air, and food products.

Market Segmentation

The chromatography resin market can be segmented based on type, technique, application, and region.

By Type: Natural polymer, synthetic polymer, and inorganic media are the primary types of chromatography resins. Natural polymers, such as agarose and cellulose, dominate the market due to their biocompatibility and versatility.

By Technique: The market is segmented into ion exchange, affinity, size exclusion, hydrophobic interaction, and others. Ion exchange and affinity chromatography are the most widely used techniques, owing to their high selectivity and efficiency.

By Application: The applications of chromatography resins span across pharmaceuticals, biotechnology, food and beverage, water and environmental analysis, and others. The pharmaceutical and biotechnology sectors account for the largest share due to their extensive use in drug development and production.

By Region: North America holds the largest market share, followed by Europe and the Asia-Pacific region. The presence of major biopharmaceutical companies, advanced healthcare infrastructure, and significant R&D investments drive the market in these regions.

Ask for Customization Report: https://intentmarketresearch.com/ask-for-customization/chromatography-resin-market-3154.html

Future Prospects

The chromatography resin market is poised for continued growth, driven by several key trends:

Personalized Medicine: The shift towards personalized medicine and targeted therapies will increase the demand for chromatography resins in the purification of specific biomolecules tailored to individual patient needs.

Biosimilars and Biobetters: The rising development of biosimilars and biobetters will fuel the demand for efficient purification techniques, further driving the chromatography resin market.

Sustainability Initiatives: Increasing focus on sustainability and green chemistry will lead to the development of eco-friendly chromatography resins, reducing environmental impact and enhancing market growth.

Emerging Markets: Rapid industrialization and advancements in healthcare infrastructure in emerging markets, particularly in Asia-Pacific and Latin America, will provide significant growth opportunities for the chromatography resin market.

Conclusion

The chromatography resin market is on a trajectory of robust growth, driven by advancements in biotechnology, increasing biopharmaceutical production, and stringent regulatory requirements. With ongoing innovations and expanding applications, the future of the chromatography resin market looks promising. Stakeholders in the industry should stay abreast of these trends to capitalize on the growth opportunities and navigate the evolving landscape effectively.

[kathansky]

Flow Cytometry is poised to grow from USD 4.25 Billion in 2023 to USD 6.99 Billion by 2031

The flow cytometry market is witnessing a period of remarkable growth and transformation, driven by advancements in technology, increasing research and diagnostic applications, and a rising demand for personalized medicine. As detailed in the latest report by SkyQuest Technology, this sector is poised for significant expansion, with various segments contributing to its dynamism. This article delves into the current trends, future outlook, and market segmentation of flow cytometry, providing a comprehensive overview for stakeholders in the healthcare and life sciences industries.

Flow Cytometry Market Overview

Flow cytometry is a powerful technology used for cell counting, cell sorting, biomarker detection, and protein engineering. Its ability to analyze multiple parameters simultaneously makes it indispensable in clinical diagnostics, immunology, oncology, and drug discovery. According to the SkyQuest report, the global flow cytometry market is expanding due to the increasing prevalence of chronic diseases, growing demand for personalized medicine, and continuous innovations in flow cytometry technology.

Global Flow Cytometry Market size was valued at USD 3.97 Billion in 2022 and is poised to grow from USD 4.25 Billion in 2023 to USD 6.99 Billion by 2031, growing at a CAGR of 7.17% in the forecast period (2024-2031).

The market is characterized by rapid technological advancements, such as the development of high-throughput and multi-parameter flow cytometers, which enhance the efficiency and accuracy of cellular analysis. Additionally, the integration of artificial intelligence and machine learning into flow cytometry systems is revolutionizing data analysis and interpretation.

Market Segmentation

Understanding the flow cytometry market requires a closer look at its segmentation. The market is segmented based on product type, application, end-user, and region. Each segment plays a crucial role in shaping the market dynamics and growth trajectories.

1. By Product Type

   - Instruments: This segment includes flow cytometers, which are further categorized into cell analyzers, cell sorters, and others. Innovations in flow cytometer designs, such as those offering enhanced sensitivity and resolution, are driving this segment's growth.

   - Reagents and Consumables: Reagents, including antibodies and dyes, are essential for conducting flow cytometry experiments. This segment is also growing due to the increasing demand for specific markers and assays.

   - Software: Advanced software solutions for data analysis and interpretation are becoming increasingly important, contributing to the market's expansion.

2. By Application

   - Clinical Applications: This includes diagnostics for diseases such as leukemia, lymphoma, and other hematological disorders. The rising incidence of these conditions and the growing need for accurate diagnostic tools are key drivers.

   - Research Applications: Flow cytometry is widely used in research settings, including cancer research, immunology, and drug discovery. The demand for high-throughput and multi-parameter analysis in research is fueling this segment.

   - Other Applications: This includes environmental and agricultural applications, where flow cytometry is used for microbial analysis and plant research.

3. By End-User

   - Hospitals and Diagnostic Laboratories: The demand for flow cytometry in hospitals and diagnostic labs is increasing due to its critical role in patient diagnosis and treatment monitoring.

   - Research Institutes: Academic and research institutions are significant users of flow cytometry for various research applications, including fundamental and applied sciences.

   - Pharmaceutical and Biotechnology Companies: These companies use flow cytometry for drug development and testing, contributing significantly to the market's growth.

4. By Region

   - North America: The region leads the market due to advanced healthcare infrastructure, high adoption rates of new technologies, and substantial research funding.

   - Europe: Europe is experiencing steady growth, driven by increasing research activities and collaborations in the healthcare sector.

   - Asia-Pacific: This region is emerging as a significant market due to rising healthcare investments, growing research activities, and a large patient population.

   - Latin America and Middle East & Africa: These regions are also expected to see growth, though at a slower pace compared to other regions, due to developing healthcare infrastructure and increasing awareness of advanced diagnostic technologies.

Chance to get a free sample: https://www.skyquestt.com/sample-request/flow-cytometry-market

Flow Cytometry Market Top Players Company Profiles

Becton, Dickinson, and Company (US) 

Danaher Corporation (US) 

Thermo Fisher Scientific, Inc. (US) 

Agilent Technologies, Inc. (US) 

Sony Group Corporation (Japan) 

Bio-Rad Laboratories, Inc. (US) 

Miltenyi Biotec GmbH (Germany) 

Enzo Biochem, Inc. (US) 

Sysmex Corporation (Japan) 

bioMérieux S.A. (France) 

Cytonome/ ST, LLC (US) 

Sartorius AG (Germany) 

Cytek Biosciences, Inc. (US) 

Union Biometrica, Inc. (US) 

Fluxion Biosciences, Inc. (US) 

Apogee Flow Systems Ltd. (UK) 

Merck KGaA (Germany) 

Beckman Coulter, Inc. (US) 

Stratedigm, Inc. (US) 

Nanocellect Biomedical (US)

Future Outlook

The flow cytometry market is set for substantial growth in the coming years, driven by ongoing technological innovations, increasing research activities, and the rising prevalence of chronic diseases. Companies are focusing on developing more advanced and user-friendly flow cytometry systems, and the integration of AI and machine learning will likely further enhance the capabilities and applications of flow cytometry.

Investments in research and development, along with strategic collaborations and partnerships, will play a crucial role in shaping the future of the flow cytometry market. Additionally, addressing challenges related to high costs and the need for skilled professionals will be key to sustaining growth and expanding market reach.

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[shrutirathi226]

Antibody discovery market: Ethical Considerations and Best Practice

Introduction to Antibody Discovery Market

The antibody discovery market is a crucial segment of the biotechnology and pharmaceutical industries, focusing on the identification and development of antibodies for therapeutic and diagnostic purposes. Key technologies include phage display and hybridoma, which facilitate the creation of monoclonal and bispecific antibodies. The market is driven by the rising prevalence of chronic diseases, technological advancements, and significant investments. Challenges include regulatory hurdles and high development costs. With applications in personalized medicine and diagnostics, the market is poised for substantial growth, particularly in regions like North America, Europe, and Asia-Pacific.

Market overview

The Antibody Discovery Market is Valued USD 6.9 billion by 2024 and projected to reach USD 14.98 billion by 2032, growing at a CAGR of 9.0% During the Forecast period of 2024–2032.This growth is driven by increasing investments in research and development, technological advancements, and the rising prevalence of chronic diseases.

Access Full Report : https://www.marketdigits.com/checkout/3712?lic=s

Major Classifications are as follows:

By Source

Humanized Antibody

Human Antibody

Chimeric Antibody

Murine Antibody

By Type

Monoclonal Antibodies (mAbs)

Polyclonal Antibodies

Recombinant Antibodies

By Technology

Phage Display

Hybridoma

Transgenic Antibody Technology

Single B Cell Technology

Others

End-user

Pharmaceutical & Biotechnology industry

Research laboratory

Academic laboratory

Key Region/Countries are Classified as Follows: ◘ North America (United States, Canada, and Mexico) ◘ Europe (Germany, France, UK, Russia, and Italy) ◘ Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) ◘ South America (Brazil, Argentina, Colombia, etc.) ◘ The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Major players in Antibody Discovery Market:

Biocytogen, Charles River Laboratories, Creative Biolabs, Danaher Corporation, Eurofins Scientific, Evotec, Fairjourney Biologics S.A, Genscript Technology Corporation, Sartorius AG, Twist Bioscience and Others.

Market Drivers in Antibody Discovery Market:

Advancements in Biotechnology: Innovations in biotechnology are enhancing the efficiency and effectiveness of antibody discovery market.

Increasing Demand for Targeted Therapies: There is a growing need for therapies that specifically target disease mechanisms, which antibodies can provide.

Prevalence of Chronic Diseases: The rising incidence of chronic diseases like cancer and autoimmune disorders is driving the demand for new antibody-based treatments.

R&D Investment: Increased investment in research and development by pharmaceutical companies is accelerating the discovery and development of new antibodies.

Market challenges in Antibody Discovery Market:

Complex Development Process: Developing antibody discovery market is a complex and time-consuming process that requires substantial resources.

Regulatory Hurdles: The stringent regulatory framework for antibody-based therapies demands extensive clinical testing and validation, which can delay market entry.

High Costs: The costs associated with research, preclinical and clinical trials, and manufacturing are significant, limiting the accessibility of antibody therapies.

Market opportunities in Antibody Discovery Market:

Expansion of Therapeutic Applications: Antibodies are increasingly being used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. This expansion opens up new avenues for research and development

Technological Advancements: Innovations such as AI and machine learning are being integrated into antibody discovery market, enhancing the speed and accuracy of identifying potential therapeutic antibodies.

Personalized Medicine: The growing trend towards personalized medicine, where treatments are tailored to individual patients, is driving demand for specific antibodies that can target unique biomarkers.

Future trends in Antibody Discovery Market:

Integration of AI and Machine Learning: AI and machine learning are increasingly being used to predict antibody structures, optimize binding affinities, and streamline the discovery process. This integration is expected to significantly accelerate the development of new antibodies.

Next-Generation Sequencing (NGS): NGS technologies are being utilized to analyze antibody repertoires at an unprecedented scale and depth, enabling the identification of rare and potent antibodies.

Bispecific and Multispecific Antibodies: There is growing interest in developing bispecific and multispecific antibodies that can target multiple antigens simultaneously, offering enhanced therapeutic efficacy.

Conclusion:

The antibody discovery market is poised for significant growth, driven by advancements in biotechnology, increasing demand for targeted therapies, and the rise of personalized medicine. Despite challenges such as high costs and regulatory hurdles, the market offers numerous opportunities, including the expansion of therapeutic applications and the integration of AI and machine learning. Future trends like next-generation sequencing and bispecific antibodies further enhance the market’s potential. Overall, the dynamic and evolving nature of the antibody discovery market makes it an exciting field for innovation and investment.